Meer bewegen en
niet te veel eten voor een lang leven.*
Insuline geeft een belangrijk signaal aan lichaamscellen om suikers te gebruiken. Bij het ouder worden worden de cellen minder gevoelig hiervoor waardoor het lichaam meer insuline moet aanmaken om de suikerwaarden onder controle te houden en zo diabetes type 2 te voorkomen. Zo is er lange tijd gedacht dat meer insuline een goede zaak is. Doch nu blijkt dat veel insuline in de hersenen niet goed is. Uit deze studie, weliswaar met muizen, blijkt dat lage waarden insuline in de hersenen zorgen voor langer leven.
Door nu voldoende te bewegen en met mate te eten voorkomt men dat de insulinewaarden in het lichaam en ook de hersenen te hoog worden en dat is goed voor een langer leven.
Reducing insulin signaling in the brain can prolong lifespan
One route to a long and healthy life may be establishing the right balance in insulin signaling between the brain and the rest of the body, according to new research from Children's Hospital Boston.
The study, published in the issue of Science, not only reinforces the value of exercising and eating in moderation, but also helps explain a paradox in longevity research.
Insulin sends a vital signal throughout the body telling cells to use sugar from the blood. But when cells become less sensitive to insulin, which often happens as we age and gain weight, the body must make more insulin to keep sugar under control and avoid type 2 diabetes. For a long time, clinicians and scientists thought that "more insulin was a good thing," says Morris White, PhD, a Howard Hughes Medical Institute investigator in Children's Division of Endocrinology, who led the new study. "But the increased insulin also gets into the brain, where it can be detrimental."
Studies in the worm C. elegans and in fruit flies show that reducing insulin signaling lengthens lifespan. But in humans and rodents, reducing insulin signaling often causes diabetes. The view that insulin could reduce lifespan is difficult to reconcile with decades of clinical practice and scientific investigation to treat diabetes.
White suspected that the key to explaining this paradox-and to maximizing both health and longevity-is to reduce insulin signaling only in the brain. To test this idea, White's team measured longevity and other characteristics in several groups of mice. In one group, they used a genetic trick to cut in half the amount of Irs2, a protein that carries the insulin signal inside the cell, in every cell of the body. Two other groups of mice were genetically engineered to have half, or nearly all, Irs2 removed only from the brain cells. Another group of normal mice served as controls.
"To our surprise, all of the engineered mice lived longer," says Akiko Taguchi, PhD, first author of the study. Even more surprising, the mice lacking Irs2 only in the brain lived almost half a year longer than the normal mice - an 18 percent increase in lifespan - despite being overweight and having higher blood insulin levels, changes that usually reduce lifespan. These long-lived mice were more active in old age, retained youthful metabolic cycles (burning sugar by day and fat by night) and retained protective levels of anti-oxidant enzymes such as superoxide dismutase, which protect against oxidative stress, or "biological rusting," in the brain and body.
The mice with normal brain Irs2 levels aged less gracefully - they lost the metabolic rhythms of youth, became more sedentary, and had reduced anti-oxidant enzymes after meals, leaving them vulnerable to cellular damage. Such damage correlates with a host of age-related diseases such as atherosclerosis, Alzheimer's disease and cancer, notes White.
White believes the study findings suggest a new approach to preventing diseases that shorten lifespan. "The engineered mice live longer because the diseases that kill them - cancer, cardiovascular disease and others - are being postponed by reducing insulin-like signaling in the brain," he says, "regardless of how much insulin there is in the rest of the body."
Drugs that regulate Irs2 signaling in the brain (but not elsewhere in the body) are one possible preventive strategy, but no such drug has yet been found. Targeted drugs will be important because Irs2 is needed in other tissues, particularly the pancreatic beta cells that produce insulin.
"The easiest way to keep insulin levels low in the brain," White says, "is old-fashioned diet and exercise." Although obesity and sedentary lifestyles tune down the body's sensitivity to insulin, exercise can bring it back and reduce blood insulin levels. Eating smaller meals keeps insulin low in the bloodstream, ensuring that less reaches the brain. The new drugs designed to fight insulin resistance and type 2 diabetes might have a similar effect.
"This study provides a new explanation of why it's good to exercise and not eat too much," says White. "It has less to do with how we look, and more to do with a healthy brain, especially in old age."
The study also calls into question the long-term effects of insulin therapy for diabetes, White adds. "High insulin should be the short term solution to insulin resistance, because it might damage the brain in the long run," he says. Better treatments for diabetes and healthy aging, he suggests, should concentrate on sensitizing the body's cells to low amounts of insulin.
The work was supported by the Howard Hughes Medical Institute, the National Institutes of Health, the Japan Society for the Promotion of Science and the Yamada Science Foundation.
Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, 11 members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 347-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School.
(Augustus 2007)
Reacties:
